Elecsys Hepatitis B Surface Antigen Quantitative Assay: Performance Evaluation and Correlation with Hepatitis B Virus DNA during 96 Weeks of Follow-up in Chronic Hepatitis B Patients
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Treatment for chronic hepatitis B aims to suppress virus replication and virus sequestration in hepatocytes. Covalently closed circular (ccc) DNA is the template for transcription of viral genes and is responsible for viral persistence. However, limited data are available for quantification of hepatitis B surface antigen (HBsAg) in Korea. Methods: We evaluated the Elecsys HBsAg II quant assay (Roche Diagnostics, USA) for within-run, between-run, and between-day precisions, linearity, carryover, and clinical specificity. In total, 156 serum samples were evaluated for correlation between HBsAg and hepatitis B virus (HBV) DNA. Serial samples were obtained from 10 patients at 0, 12, 24, 48, 72, and 96 weeks during follow-up. Results: The assay detected HBsAg in a linear range of 0.5-48,696 IU/mL. Within-run, between- run, and between-day CVs were 2.9-4.1%, 0-1.5%, and 1.5-4.9%, respectively. Cross-reactivity between potentially interfering substances was absent, and the carryover rate was 0.00002%. The correlation of measurements between the Elecsys assay and HBV DNA PCR was weak (r=0.438, P =0.002). For predicting virologic response, cutoff values of 10,275 IU/mL and 3,846 IU/mL at 12 and 24 weeks after treatment initiation showed positive predictive values of 77.1% and 85% and negative predictive values of 84.6% and 50%, respectively. Conclusions: The Elecsys HBsAg II quant assay showed good performance for precision, linearity, carryover rate, and specificity. HBsAg level at baseline, 12 weeks, and 24 weeks after treatment initiation can predict virologic response, and the assay can be used for HBsAg quantification in clinical practice.
Abstract
Background: Treatment for chronic hepatitis B aims to suppress virus replication and virus sequestration in hepatocytes. Covalently closed circular (ccc) DNA is the template for transcription of viral genes and is responsible for viral persistence. However, limited data are available for quantification of hepatitis B surface antigen (HBsAg) in Korea. Methods: We evaluated the Elecsys HBsAg II quant assay (Roche Diagnostics, USA) for within-run, between-run, and between-day precisions, linearity, carryover, and clinical specificity. In total, 156 serum samples were evaluated for correlation between HBsAg and hepatitis B virus (HBV) DNA. Serial samples were obtained from 10 patients at 0, 12, 24, 48, 72, and 96 weeks during follow-up. Results: The assay detected HBsAg in a linear range of 0.5-48,696 IU/mL. Within-run, between- run, and between-day CVs were 2.9-4.1%, 0-1.5%, and 1.5-4.9%, respectively. Cross-reactivity between potentially interfering substances was absent, and the carryover rate was 0.00002%. The correlation of measurements between the Elecsys assay and HBV DNA PCR was weak (r=0.438, P =0.002). For predicting virologic response, cutoff values of 10,275 IU/mL and 3,846 IU/mL at 12 and 24 weeks after treatment initiation showed positive predictive values of 77.1% and 85% and negative predictive values of 84.6% and 50%, respectively. Conclusions: The Elecsys HBsAg II quant assay showed good performance for precision, linearity, carryover rate, and specificity. HBsAg level at baseline, 12 weeks, and 24 weeks after treatment initiation can predict virologic response, and the assay can be used for HBsAg quantification in clinical practice.
참고문헌 (24)
- Lin LY, "with covalently closed circular DNA in HBeAg- negative patients", J Med Virol, 82, pp.1494~1500 (2010)
- Lee WM., "Hepatitis B virus infection", N Engl J Med, 337, pp.1733~1745 (1997)
- Nguyen T, "Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia", J Hepatol, 52, pp.508~513 (2010)
- Jaroszewicz J, "Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective", J Hepatol, 52, pp.514~522 (2010)
- Thompson AJ, "Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers", Hepatology, 51, pp.1933~1944 (2010)
- Sonneveld MJ, "A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B", J Clin Virol, 51, pp.175~178 (2011)
- Wursthorn K, "Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum", J Clin Virol, 50, pp.292~296 (2011)
- National Committee for Clinical Laboratory Standards, "Evaluation of precision performance of puantitative measurement methods: Approved guideline, EP5-A2", National Committee for Clinical Laboratory Standards, ~ (2004)
- Tholen DW, "Evaluation of linearity using the newly approved NCCLS EP6-A protocol", Clin Lab News, 30, pp.10~12 (2004)
- National Committee for Clinical Laboratory Standards, "Preliminary evaluation of quantitative clinical laboratory methods: Approved guideline, EP10-A2. Second edition", National Committee for Clinical Laboratory Standards, ~ (2002)
- National Committee for Clinical Laboratory Standards, "Protocols for determination of limits of detection and limits of quantitation: Approved guideline EP17-A", National Committee for Clinical and Laboratory Standards, ~ (2004)
- Glass DC, "Estimating mean exposures from censored data: exposure to benzene in the Australian petroleum industry", Ann Occup Hyg, 45, pp.275~282 (2011)
- Chan HL, "Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report", J Hepatol, 55, pp.1121~1131 (2011)
- Moucari R, "Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B", Liver Int, 31(S1), pp.122~128 (2011)
- Deguchi M, "Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay", J Virol Methods, 115, pp.217~222 (2004)
- Ozaras R, "Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment", Dig Dis Sci, 53, pp.2995~2998 (2008)
- Weigand J, "A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels", Antivir Ther, 13, pp.547~554 (2008)
- Chen J, "Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a", Antiviral Res, 81, pp.88~91 (2009)
- Moucari R, "Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAgnegative patients", Hepatology, 49, pp.1151~1157 (2009)
- 조유경, "만성 B형간염 환자에서 항바이러스 치료 중 혈청 HBV DNA 및 HBsAg 정량의 새로운 이해", 대한소화기학회지, 57(3), pp.144~149 (2011), 대한소화기학회
- Chan HL, "Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response", Clin Gastroenterol Hepatol, 5, pp.1462~1468 (2007)
- Piratvisuth T, "Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients" (2011), Hepatology Int
- Lee MH, "Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B", J Med Virol, 83, pp.1178~1186 (2011)
- Cai W, "On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients", J Clin Virol, 48, pp.22~26 (2010)